Kessler Paul D. 4
4 · NABI BIOPHARMACEUTICALS · Filed Jan 7, 2011
Insider Transaction Report
Form 4
Kessler Paul D.
SVP Clinical, Med. & Reg.; CMO
Transactions
- Sale
Common Stock
2011-01-05$5.65/sh−2,985$16,869→ 95,267 total
Footnotes (2)
- [F1]This disposition was made to fund the Reporting Person's tax obligation arising from the vesting of restricted stock.
- [F2]This disposition was effected pursuant to a 10b5-1 trading plan.